OMITTED

What the news leaves out.

← Omitted front page

FDA Delays Abortion Pill Safety Review Until Next Year

5 sources · updated 2026-10-10
Left 0% Center 50% Right 50%
0 left · 1 center · 1 right

What happened

The U.S. Food and Drug Administration said in a Wednesday court filing that it expects to finish a safety study of the abortion pill mifepristone by mid-December and to issue a final report no later than March 2027, and that it will not amend the drug’s Risk Evaluation and Mitigation Strategy until that review is complete. The filing was a court-ordered progress report in Louisiana v. FDA, a suit before U.S. District Judge David Joseph of the Western District of Louisiana challenging the agency’s 2021 and 2023 decisions that allowed mifepristone to be prescribed by telehealth and sent by mail instead of dispensed in person. The FDA said it will use its Sentinel database to compare side effects among roughly 100,000 women who took mifepristone with those of surgical abortion through 10 weeks’ gestation, and that it will also consider pending citizen petitions. Mifepristone was approved in 2000; Health Secretary Robert F. Kennedy Jr. ordered this review after a conservative think tank claimed higher complication rates than the FDA had reported. In May, the 5th U.S. Circuit Court of Appeals granted Louisiana’s request to restore nationwide in-person dispensing, but the Supreme Court blocked that order while the case proceeds.
Sourcing check · Fully on the record · 5 articles

4 of 4 articles cite a named source for the story. It was on the record from the first report.

What these terms mean and how they're counted
On the record · names a source 4 of 4
On the record means the article cites a source by name for the story's main claim: a person, or an institution speaking officially, such as a company statement or a named agency's spokesperson. The opposite is an unnamed source. The count is how many of the counted articles cite at least one such source; the names are everyone named across them, each once however the articles spell it. Here: FDA, Justice Department, Gavin Oxley and Food and Drug Administration
Primary evidence · cites a document or data 4 of 4
Primary evidence means the article cites a record you could check yourself: a court filing or ruling, a dataset or report, a recording or transcript, an official statement or press release, market data. A quote is not a document. The count is how many articles cite one. Here: court document, official statement, court filing, court order
Credits another outlet 0 of 4
The article says the story comes from another outlet's reporting (“first reported by Reuters”). Those articles relay the story; they are not independent confirmation. Here: Each article presents its own reporting.
Unnamed sources 0 of 4
The main claim is attributed to people who are not identified: “people familiar with the matter”, “officials said”. The count is how many articles do this.
How it developed
When the first report landed and whether it named anyone; when the first named source and the first document appeared. Here: First report Oct 8, 01:29 UTC by NBC News, naming its source. First document in the first report, from NBC News (court document).
Not counted 1
Opinion, analysis and video pieces, and articles too short to assess. Every count above is out of the counted articles. An article republished under a new headline is one article.
This is about who is cited, not whether the story is true. Each source below says what it names. How we count
Omitted — what each side leaves out

Unpacked

Left-leaning coverage never reports the higher complication rate that conservative researchers used to demand this review, and right-leaning coverage never reports the much lower rate in the existing literature. Serious reactions sit below 0.5% of patients in NBC News. The Federalist cites serious complications for more than one in ten women. That missing contrast is what makes the same March date look like routine science or like indifference to common injuries. Left-leaning coverage leads with the March end date and how the study will be built. Right-leaning coverage leads with the years already spent since the safety pledge. NBC News foregrounds a comparison with surgical abortion among roughly 100,000 women. The Federalist opens on a finish line "2 Years After Pledging To Review Safety Concerns." The court asked for a progress report, not a verdict on those two rates. None of the coverage asks whether the December results will be made public, or only absorbed into a March report after the agency has already chosen whether to tighten access.
Bottom line

NBC News can walk you through the March delay without ever mentioning a one-in-ten complication rate. The Federalist can walk you through that delay without the much lower figure long cited for the same pill.

The receipts — 6 facts one side's coverage lacks
  • Less than 0.5% of women who take mifepristone have serious adverse reactions numberin NBC News · absent from right-leaning coverage
  • More than one in 10 women who take mifepristone suffer serious complications such as hemorrhage or infection numberin The Federalist, The Daily Wire · absent from left-leaning coverage
  • The think tank paper that prompted the review was neither peer-reviewed nor published in a medical journal contextin NBC News · absent from right-leaning coverage
  • Hundreds of peer-reviewed studies have found mifepristone to be safe and effective contextin NBC News · absent from right-leaning coverage
  • The FDA plans to finalize the safety review in March 2027 official statementin The Federalist · absent from left-leaning coverage
  • The Louisiana judge warned that if FDA fails to complete its review and make any necessary REMS revisions within a reasonable timeframe, the court's analysis will change legal rulingin The Federalist · absent from left-leaning coverage
The Left View
Left-leaning outlets frame the wait as leaving in place a drug that “hundreds of peer-reviewed studies have found to be safe and effective,” with serious adverse reactions in less than 0.5% of users, and they call the think-tank analysis that prompted the review unpublished “junk science.” NBC News notes that the report date falls months after the Nov. 3 midterm elections, “when abortion access is among the concerns for voters,” and that it is unclear what an FDA without a permanent commissioner will conclude; it also reports that President Trump’s nominee, Dr. Heidi Overton, has described medication abortion as “dangerous to women” and “repeatedly sidestepped questions” about whether the pill is safe. The Hill says the agency “won’t impose any new restrictions on the pill before that point,” a stance “likely to further anger anti-abortion activists.”
The Right View
Right-leaning outlets cast the March 2027 date as the FDA delaying action “2 years after pledging to review safety concerns” and slow-walking past the 2026 midterms, stressing that “no review is required” to restore in-person dispensing. The Federalist quotes pro-life leaders saying there is “no public evidence this review has actually begun,” and reports the agency will not consider changing the REMS until after the study. They cite Charlotte Lozier Institute analyses that the 2021 REMS review was “insufficient” and “may have even been biased towards pro-abortion groups,” that more than one in 10 women suffer serious complications such as hemorrhage or infection, and that the risk of a life-threatening event is “at least 22 times higher” than FDA and manufacturer figures. In The Daily Wire, SBA Pro-Life America president Marjorie Dannenfelser writes that mifepristone “continues to take more U.S. lives than fentanyl, cocaine, and heroin combined,” that an estimated 75,000 unborn babies in pro-life states will die from mail-order drugs in five months, and that abusers are “empowered by the FDA’s inaction”; she argues the Justice Department should settle the Louisiana case now.
Our Take (balanced)
The left’s strongest argument is the accumulated peer-reviewed record — including serious-complication rates below 0.5% — that the pill is safe, which they contrast with unpublished think-tank claims they reject as junk science, treating a large new FDA study as the proper basis for any access change. The right’s strongest argument is that later independent analyses already show complication rates around one in ten and a far higher risk of life-threatening events than the FDA has acknowledged, so in-person dispensing could be restored without waiting for a review that has stretched past two years and the midterms. The central unresolved tension is whether those competing bodies of evidence already suffice to keep or to roll back mail-order access, or whether only the unfinished FDA study can settle the safety dispute — and whether the post-election timeline is scientific caution or political delay.

5 sources

More stories

The week's bottom lines, in your inbox

One email a week: the five stories that mattered and what they actually mean. Free.